12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Nicox, Rapid Pathogen Screening deal

Rapid granted NicOx exclusive, worldwide rights to commercialize several ophthalmic diagnostics.The deal includes AdenoPlus adenoviral conjunctivitis diagnostic and two diagnostics in development - RPS-AP for detecting adenoviral and allergic conjunctivitis and RPS-OH to diagnose ocular herpes. In the U.S., NicOx...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >